CA2273202A1 - Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees - Google Patents

Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees Download PDF

Info

Publication number
CA2273202A1
CA2273202A1 CA002273202A CA2273202A CA2273202A1 CA 2273202 A1 CA2273202 A1 CA 2273202A1 CA 002273202 A CA002273202 A CA 002273202A CA 2273202 A CA2273202 A CA 2273202A CA 2273202 A1 CA2273202 A1 CA 2273202A1
Authority
CA
Canada
Prior art keywords
jam
protein
ser
modifier
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002273202A
Other languages
English (en)
Inventor
Elisabetta Dejana
Ines Martin Padura
David Simmons
Lisa Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2273202A1 publication Critical patent/CA2273202A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Crystal (AREA)
  • Photometry And Measurement Of Optical Pulse Characteristics (AREA)

Abstract

L'invention concerne une protéine transmembranaire localisée dans des jonctions serrées. La protéine est exprimée dans des cellules endothéliales, épithéliales, mégacaryocytaires ou dans des plaquettes. La protéine est appelée molécule d'adhésion jonctionnelle (JAM). On décrit la séquence amino-acide de la JAM humaine ou murine, ainsi que les séquences d'ADN, les gènes et les protéines recombinées ou peptides exprimés par les gènes ou des fragments de ces gènes. On décrit en outre des anticorps se liant plus particulièrement à la JAM ou partie de la JAM, des modificateurs (inhibiteurs et inducteurs, par exemple) de la polymérisation de la JAM transmembranaire, les anticorps et le modificateur utilisés comme réactifs présentés dans des trousses de diagnostic, ainsi que des emplois du modificateur, en tant qu'adjuvant des vaccins et principe actif, dans des médicaments. Enfin, l'invention concerne aussi des animaux ou des cellules transgéniques qui surexpriment la JAM ou chez qui la JAM est absente.
CA002273202A 1996-12-04 1997-12-01 Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees Abandoned CA2273202A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9604470A SE9604470D0 (sv) 1996-12-04 1996-12-04 Transmembrane component of tight junction
SE9604470-6 1996-12-04
PCT/EP1997/006723 WO1998024897A1 (fr) 1996-12-04 1997-12-01 Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees

Publications (1)

Publication Number Publication Date
CA2273202A1 true CA2273202A1 (fr) 1998-06-11

Family

ID=20404862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002273202A Abandoned CA2273202A1 (fr) 1996-12-04 1997-12-01 Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees

Country Status (7)

Country Link
EP (1) EP0948621A1 (fr)
JP (1) JP2001506847A (fr)
AU (1) AU5657898A (fr)
CA (1) CA2273202A1 (fr)
SE (1) SE9604470D0 (fr)
WO (1) WO1998024897A1 (fr)
ZA (1) ZA9710794B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027098A2 (fr) * 1997-11-21 1999-06-03 Genentech, Inc. Antigenes apparentes a a33 et leurs utilisations pharmacologiques
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US20040141972A1 (en) 1997-11-21 2004-07-22 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ATE500328T1 (de) 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
US6391855B1 (en) 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
AU2002315404A1 (en) * 2001-07-16 2003-03-03 Eli Lilly And Company Extracellular junctional adhesion molecules
WO2006008076A2 (fr) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Procedes et agents stimulant la reponse immunitaire
JP2010504955A (ja) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
WO2009137605A2 (fr) 2008-05-06 2009-11-12 Genentech, Inc. Variants de crig à maturation d'affinité

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665701A (en) * 1994-11-17 1997-09-09 The Research Foundation Of State University Of New York Platelet membrane glycoprotein F11 and polypeptide fragments thereof

Also Published As

Publication number Publication date
JP2001506847A (ja) 2001-05-29
EP0948621A1 (fr) 1999-10-13
SE9604470D0 (sv) 1996-12-04
ZA9710794B (en) 1998-06-04
AU5657898A (en) 1998-06-29
WO1998024897A1 (fr) 1998-06-11

Similar Documents

Publication Publication Date Title
Newton et al. Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31
CA2305385C (fr) Homologues toll humains
US20030077826A1 (en) Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
HUE025347T2 (en) NOGO receptor binding protein
CZ111996A3 (en) Novel reacting mitotic phosphoprotein mitosine
WO1998024897A1 (fr) Molecule d'adhesion jonctionnelle (jam), proteine transmembranaire de jonctions serrees
CA2245956A1 (fr) Anticorps monoclonaux specifiques des cadherines de cellules endotheliales et leurs utilisations
Tsurudome et al. Function of fusion regulatory proteins (FRPs) in immune cells and virus-infected cells
JP3660880B2 (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
KR100943197B1 (ko) 모발성장을 촉진시키는 올리고펩타이드
TWI356097B (en) Ccn1 compositions and methods
EP1274731A1 (fr) Homologue inhibiteur d'activateur de facteur de croissance des hepatocytes humains
JP2001506481A (ja) ブラジキニンｂ▲下１▼レセプターをコードするｄｎａ
CA2298066A1 (fr) Procedes et compositions permettant de reguler le transport des proteines dans le noyau
Basmaciogullari et al. Mapping the CD4 binding domain of gp17, a glycoprotein secreted from seminal vesicles and breast carcinomas
CA2282830A1 (fr) Sp.alpha.: un polypeptide de recepteur capteur contenant des domaines riches en cysteine, et ses anticorps monoclonaux
US20120142099A1 (en) Novel bak binding protein, dna encoding the protein, and methods of use thereof
US20040248257A1 (en) SPEX compositions and methods of use
US20050048483A1 (en) Novel secreted proteins and their uses
WO2002016578A2 (fr) Nouvelles proteines secretees et procedes d'utilisation de ces dernieres
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
US20040038369A1 (en) Airway-specific trypsin-like enzymes and method of using the same
CA2489780A1 (fr) Methodes de prevention ou de traitement d'un etat pathologique lie a l'angiogenese
WO2005092921A2 (fr) Variants d'epissage du facteur de croissance placentaire, utilisations de ces derniers
EP1500663A1 (fr) Protéines secrétées et leurs utilisations.

Legal Events

Date Code Title Description
FZDE Discontinued